6 reports

Leishmaniasis (Kala-Azar) - Overview Leishmaniasis (Kala-Azar) - Therapeutics Development NUMBER OF PRODUCTS UNDER DEVELOPMENT FOR LEISHMANIASIS (KALA-AZAR), H## 2018 PIPELINE OVERVIEW NUMBER OF PRODUCTS UNDER DEVELOPMENT FOR LEISHMANIASIS (KALA-AZAR), H## 2018 Phase III ## ## Phase II ## ## Phas

  • Drug Development
  • Therapy
  • United States
  • World
  • Product Initiative
  • Stage Of Development
  • BIOMARKER BASED DIAGNOSTIC ASSAY - CARDIAC DISEASE - PRODUCT DESCRIPTION

UCD offers inter-institutional collaborative programs and research centers in the areas which include sensor web technologies, systems biology and nanobiotechnology and biopharmaceuticals, among others.

  • Drug Development
  • Healthcare
  • Surgery
  • United States
  • Pfizer Inc.

Nanobiotechnology.

  • Drug Development
  • Surgery
  • CAP-1002 group
  • Capricor Therapeutics, Inc.
  • Mirna Therapeutics, Inc.
  • UNIVERSITY COLLEGE DUBLIN PIPELINE PRODUCTS & ONGOING CLINICAL TRIALS OVERVIEW
  • MRM BASED BIOMARKER ASSAY - PROSTATE CANCER - PRODUCT STATUS

UCD offers inter-institutional collaborative programs and research centers in the areas which include sensor web technologies, systems biology and nanobiotechnology and biopharmaceuticals, among others.

  • Drug Development
  • Healthcare
  • Prostate Cancer
  • Surgery
  • bioMerieux S.A.
  • 3.7 PATENT TRENDS

New area of research called nanobiotechnology has also emerged.

  • Drug Development
  • Surgery
  • World
  • Market Size
  • DePuy Synthes, Inc.
  • UNIVERSITY COLLEGE DUBLIN PIPELINE PRODUCTS & ONGOING CLINICAL TRIALS OVERVIEW
  • Cardiac Markers Tests Companies and Product Overview

Consolidated net profit : € ## ##. ## million, equal to ## ##. ## % of revenues, + ##. ##% compared to € ## ##. ## million in 2013.

  • Chronic Disease
  • Clinical Trial
  • Drug Development
  • Surgery
  • Company